Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AGEN

AGEN - Agenus Inc Stock Price, Fair Value and News

$3.12-0.07 (-2.19%)
Market Closed

20/100

AGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

AGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.59

Target 3M

$2.93

Target 6M

$2.75

AGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGEN Price Action

Last 7 days

-8.2%

Last 30 days

-2.2%

Last 90 days

-18.1%

Trailing 12 Months

-12.4%

AGEN RSI Chart

AGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGEN Valuation

Market Cap

106.1M

Price/Earnings (Trailing)

-2.7

Price/Sales (Trailing)

0.99

EV/EBITDA

-1.53

Price/Free Cashflow

-1.19

AGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.59

Target 3M

$2.93

Target 6M

$2.75

AGEN Fundamentals

AGEN Revenue

Revenue (TTM)

106.8M

Rev. Growth (Yr)

20.4%

Rev. Growth (Qtr)

17.69%

AGEN Earnings

Earnings (TTM)

-39.3M

Earnings Growth (Yr)

195.09%

Earnings Growth (Qtr)

312.95%

AGEN Profitability

Operating Margin

98.93%

EBT Margin

-112.98%

Return on Equity

13.98%

Return on Assets

-16.79%

Free Cashflow Yield

-84.17%

AGEN Investor Care

Shares Dilution (1Y)

44.97%

Diluted EPS (TTM)

-2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202599.5M101.7M106.8M0
2024161.4M159.6M160.4M103.5M
202395.0M99.4M100.9M156.3M
2022309.9M320.1M89.9M98.0M
202184.8M68.5M306.7M295.7M
202085.3M96.5M91.4M88.2M
2019115.0M114.9M122.0M150.0M
201841.4M39.8M38.3M36.8M
201743.6M41.2M40.1M42.9M
201626.8M27.0M24.6M22.6M
201510.2M13.5M18.8M24.8M
20142.7M4.9M5.8M7.0M
20133.7M3.9M3.7M3.0M
201215.5M15.3M15.5M16.0M
20113.1M3.1M3.1M2.8M
20100003.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Agenus Inc

AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEagenusbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES533

Agenus Inc Frequently Asked Questions

AGEN is the stock ticker symbol of Agenus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Agenus Inc is 106.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AGEN's fair value in chart for subscribers.

The fair value guage provides a quick view whether AGEN is over valued or under valued. Whether Agenus Inc is cheap or expensive depends on the assumptions which impact Agenus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGEN.

As of Wed Jan 28 2026, AGEN's PE ratio (Price to Earnings) is -2.7 and Price to Sales (PS) ratio is 0.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Agenus Inc has provided -0.258 (multiply by 100 for percentage) rate of return.